MAIA Biotechnology has reported positive initial efficacy results from its Phase II THIO-101 trial, Part C, involving its ...

Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced ...

The second clinical case presents a patient with ROS1 fusion-positive advanced NSCLC who achieved partial response on ...

MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable ...

The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.

Data from the COMPEL trial support extending osimertinib (Tagrisso, AstraZeneca) therapy to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment ...

Divarasib outperformed existing therapies in patients with KRAS G12C non-small cell lung cancer (NSCLC).

Dr. Konduri provides an overview of the current frontline treatment landscape for metastatic EGFR-positive NSCLC. Targeted therapies are the cornerstone, including the tyrosine kinase inhibitor ...

Key market opportunities in lung cancer therapeutics include the rising incidence of lung cancer, innovations in therapeutics ...

If you have non-small-cell lung cancer (NSCLC) with an EGFR mutation, your health care provider may recommend a new medicine called Datroway (datopotamab deruxtecan-dlnk). NSCLC is the most common ...